July 24, 2017 / 12:27 PM / 2 years ago

BRIEF-Shionogi ‍announces positive top-line results for S-033188 phase 3 study

July 24 (Reuters) - Shionogi & Co Ltd:

* Shionogi - ‍announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients

* Shionogi - ‍time to alleviation of symptoms (TTAS) was significantly reduced with s-033188 compared to placebo​

* Shionogi & Co Ltd - ‍s-033188 was well tolerated​

* Shionogi & Co Ltd - ‍based on results from capstone-1, shionogi plans to submit a new drug application (NDA) to PMDA in Japan later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below